Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Meiji Seika Pharma Co., Ltd. reported beneficial ownership in Arcturus Therapeutics Holdings Inc. of 2,466,395 shares issuable to and to be held directly by Meiji, representing 7.88% of the class. Meiji reported sole voting and dispositive power over the shares, with zero shared voting or dispositive power.
Meiji based the percentage on 28,822,514 shares outstanding as of November 3, 2026, plus the 2,466,395 shares issuable under a Securities Purchase Agreement dated November 16, 2026, for a stated total of 31,288,909 shares.
Key Figures
Beneficially owned shares:2,466,395 sharesOwnership percentage:7.88%Shares outstanding:28,822,514 shares+1 more
4 metrics
Beneficially owned shares2,466,395 sharesShares issuable to and to be held directly by Meiji Seika Pharma
Ownership percentage7.88%Percentage of the class reported by Meiji Seika Pharma
Shares outstanding28,822,514 sharesAs of November 3, 2026
Stated share total for ownership calculation31,288,909 sharesIncludes 28,822,514 shares outstanding and 2,466,395 shares issuable under the Securities Purchase Agreement
Key Terms
beneficially owned, sole voting power, sole dispositive power, Shares issuable
4 terms
beneficially ownedregulatory
"Amount beneficially owned: 2,466,395 Shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole voting powerregulatory
"Sole Voting Power 2,466,395.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive powerregulatory
"Sole Dispositive Power 2,466,395.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Shares issuabletechnical
"2,466,395 Shares issuable to, and to be held directly"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many ARCT shares does Meiji Seika Pharma report beneficially owning?
Meiji reports 2,466,395 shares issuable to and to be held directly by it, equal to 7.88% of the class.
How did Meiji Seika Pharma calculate its 7.88% ARCT ownership?
It used 31,288,909 shares as the stated total: 28,822,514 shares outstanding as of November 3, 2026, plus 2,466,395 shares issuable under the Securities Purchase Agreement dated November 16, 2026.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Arcturus Therapeutics Holdings Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
03969T109
(CUSIP Number)
11/16/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
03969T109
1
Names of Reporting Persons
Meiji Seika Pharma Co., Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
JAPAN
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
2,466,395.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
2,466,395.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,466,395.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.88 %
12
Type of Reporting Person (See Instructions)
CO
Comment for Type of Reporting Person: With respect to Rows 5 through 9 and Row 11 above, the amounts reported reflect 2,466,395 shares of Common Stock issuable to, and to be held directly by, the Reporting Person.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Arcturus Therapeutics Holdings Inc.
(b)
Address of issuer's principal executive offices:
10285 Science Center Drive, San Diego, California 92121
Item 2.
(a)
Name of person filing:
Meiji Seika Pharma Co., Ltd. (the "Reporting Person")
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of the Reporting Person is:
2-4-16, Kyobashi, Chuo-ku,
Tokyo 104-8002, Japan
(c)
Citizenship:
Japan
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP Number(s):
03969T109
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by this Item 4(a) is set forth in Row 9 of the cover page hereto and is incorporated herein by reference.
The number of Shares reported as beneficially owned by the Reporting Person consists of 2,466,395 Shares issuable to, and to be held directly by, the Reporting Person.
The percentage reported is based on 28,822,514 Shares outstanding as of November 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 5, 2026, plus 2,466,395 Shares issuable to the Reporting Person pursuant to the Securities Purchase Agreement dated November 16, 2026, for a total of 31,288,909 Shares outstanding.
(b)
Percent of class:
7.88 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by this Item 4(c)(i) is set forth in Row 5 of the cover page hereto and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by this Item 4(c)(ii) is set forth in Row 6 of the cover page hereto and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by this Item 4(c)(iii) is set forth in Row 7 of the cover page hereto and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by this Item 4(c)(iv) is set forth in Row 8 of the cover page hereto and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.